- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07727148
FASC: Fish Allergy in Spanish Children - A Study of New Cases of Fish Allergy in Children and Adolescents (FASC)
IgE-Mediated Fish Allergy in Spanish Children and Adolescents: A Multicenter Prospective Study of New-Onset Cases and Sensitization Profiles.
Fish allergy is one of the leading causes of food-induced allergic reactions in children, but the clinical presentation and patterns of sensitization vary considerably among patients and geographical regions. This prospective multicenter observational study aims to characterize children and adolescents with newly diagnosed IgE-mediated fish allergy in Spain.
Clinical information, diagnostic test results, and molecular sensitization profiles will be collected using standardized procedures across participating centers. Molecular allergy assessment will include component-resolved diagnostics to evaluate sensitization to major fish allergens and other relevant allergenic protein families. The study will also assess disease severity, quality of life, and regional differences in sensitization patterns.
The results are expected to improve the understanding of pediatric fish allergy in Spain and contribute to more accurate diagnosis, risk assessment, and personalized management of affected patients.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
Fish allergy is a major cause of IgE-mediated food allergy in children and is associated with a wide spectrum of clinical manifestations, ranging from mild reactions to severe anaphylaxis. Current knowledge of pediatric fish allergy is limited by geographical differences in dietary habits, fish species consumed, and patterns of allergen sensitization. Although component-resolved diagnostics have improved the characterization of fish allergy, comprehensive multicenter studies in children remain scarce.
The FASC study is a prospective, multicenter, observational study conducted in Spain to characterize children and adolescents with newly diagnosed IgE-mediated fish allergy. Consecutive eligible patients will be recruited in participating pediatric allergy units using standardized diagnostic and data collection procedures. Clinical information, allergy history, skin testing, serum specific IgE measurements, and molecular sensitization profiles will be collected. When clinically indicated, oral food challenges will be performed according to international recommendations and routine clinical practice.
The study aims to describe clinical phenotypes, molecular sensitization patterns, disease severity, quality of life, and geographical variability across Spain. The findings are expected to improve the understanding of pediatric fish allergy, support the identification of clinically relevant sensitization profiles, and contribute to more accurate diagnosis and individualized patient management.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Lapsi
Hyväksyy terveitä vapaaehtoisia
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
- Children and adolescents aged 0 to 17 years (up to 18 years of age).
- First clinical episode compatible with IgE-mediated fish allergy.
- Evidence of allergic sensitization demonstrated by at least one of the following:
- Positive skin prick test (wheal diameter ≥3 mm compared with the negative control); or
- Serum specific IgE ≥0.35 kUA/L to at least one fish species or fish allergen component.
- Written informed consent obtained from the parent(s) or legal guardian(s), and assent from participants aged 12 years or older, when applicable.
Exclusion Criteria:
- Age ≥18 years.
- Non-IgE-mediated fish allergy (e.g., fish-induced FPIES).
- Severe dermographism, chronic urticaria, or severe atopic dermatitis preventing reliable interpretation of skin prick testing.
- Inability to complete the diagnostic procedures required by the study.
- Absence of informed consent or, when applicable, participant assent.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Prevalence of sensitization to clinically relevant fish allergen components.
Aikaikkuna: Baseline (Day 1)
|
Distribution of molecular sensitization profiles to clinically relevant fish allergen components and allergenic protein families in children and adolescents with newly diagnosed IgE-mediated fish allergy, as determined by component-resolved diagnostics performed at study enrollment.
|
Baseline (Day 1)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Sensitization to individual fish allergen components
Aikaikkuna: Baseline (Day 1)
|
Frequency and distribution of sensitization to individual fish allergen components and allergenic protein families measured by component-resolved diagnostics.
|
Baseline (Day 1)
|
|
Specific IgE sensitization profile
Aikaikkuna: Baseline (Day 1)
|
Serum specific IgE sensitization to fish species and allergenic components determined using standardized laboratory methods.
|
Baseline (Day 1)
|
|
Oral food challenge outcome
Aikaikkuna: During the diagnostic evaluation (up to 3 months after baseline (Day 1))
|
Results of oral food challenges, including confirmation of clinical allergy and identification of tolerated fish species, when clinically indicated.
|
During the diagnostic evaluation (up to 3 months after baseline (Day 1))
|
|
Health-related quality of life
Aikaikkuna: Baseline (Day 1) and at completion of the diagnostic evaluation (up to 3 months after baseline (Day 1))
|
Health-related quality of life assessed using validated food allergy-specific quality-of-life questionnaires.
|
Baseline (Day 1) and at completion of the diagnostic evaluation (up to 3 months after baseline (Day 1))
|
|
Geographical variability in sensitization profiles
Aikaikkuna: Through study completion, an average of 18 months
|
Comparison of molecular sensitization profiles and clinical characteristics across participating regions in Spain.
|
Through study completion, an average of 18 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- FASC-2026-001
- R-0012/26 (Muu tunniste: Clinical Research Ethics Committee (CEIm), Hospital Infantil Universitario Niño Jesús, Madrid, Spain)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .